In addition, several other antiangiogenic compounds such as razoxane, bryostatin-1, TNP-470, or anti-VEGF antibodies have shown some activity with even objective tumour responses in RCC (Stadler et al, 1999; Braybrooke et al, 2000; Pagliaro et al, 2000; Yang et al, 2003). This evidence concerns the gene VEGFA and renal cell adenocarcinoma.